Literature DB >> 10924789

IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin.

M R Fontana1, E Monaci, L Yanqing, Q Guoming, G Duan, R Rappuoli, M Pizza.   

Abstract

Two mutants of cholera toxin (CTS106 containing a Pro106-->Ser substitution and CTK63 containing a Ser63-->Lys substitution) with greatly reduced or no toxicity respectively, were expressed in the naturally attenuated IEM101 Vibrio cholerae strain (El Tor, Ogawa) which does not express cholera toxin (CT). Expression was driven by the natural promoter of CT, or by a promoter known to induce strong in vivo expression such as nirB. In the rabbit ileal loop assay, where 10(4) wild type bacteria were sufficient to induce fluid accumulation, 10(9) IEM101 expressing CTS106 bacteria were needed to induce some fluid accumulation, while IEM101 expressing CTK63 was inactive, even when 10(10) cells were used. When used to immunize mice intranasally, all bacteria induced vibriocidal antibodies; however, anti-CT antibodies were not induced by bacteria expressing low levels of CTK63 under the control of the ct promoter. Anti-CT antibodies were successfully induced by bacteria expressing high levels of CTK63 under the control of the nirB promoter, or by bacteria expressing low levels of CTS106. These data show that antibodies against cholera toxin can be induced in vivo by high level expression of a non toxic mutant, or by using a mutant with residual ADP-ribosyltransferase activity. In conclusion, we have shown that IEM101, a naturally attenuated Vibrio strain known to be safe and immunogenic in humans, can be engineered to express immunogenic levels of CTK63, and may represent a good candidate for vaccination against cholera.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924789     DOI: 10.1016/s0264-410x(00)00137-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Construction and characterization of a thyA mutant derived from cholera vaccine candidate IEM101.

Authors:  Fenggang Yu; Guoming Qi; Yanqing Liu; Shouyi Gao; Biao Kan
Journal:  Mol Biotechnol       Date:  2005-03       Impact factor: 2.695

2.  Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines.

Authors:  Shifeng Wang; Yuhua Li; Huoying Shi; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

3.  Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.

Authors:  Weili Liang; Shixia Wang; Fenggang Yu; Lijuan Zhang; Guoming Qi; Yanqing Liu; Shouyi Gao; Biao Kan
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 4.  Exploiting cholera vaccines as a versatile antigen delivery platform.

Authors:  Anisia J Silva; Francis O Eko; Jorge A Benitez
Journal:  Biotechnol Lett       Date:  2007-11-16       Impact factor: 2.461

5.  Use of stabilized luciferase-expressing plasmids to examine in vivo-induced promoters in the Vibrio cholerae vaccine strain CVD 103-HgR.

Authors:  Cara E Morin; James B Kaper
Journal:  FEMS Immunol Med Microbiol       Date:  2009-07-01

6.  The hows and whys of constructing a native recombinant cholera vaccine.

Authors:  Mina Boustanshenas; Bita Bakhshi
Journal:  Bioengineered       Date:  2013-09-16       Impact factor: 3.269

7.  Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria.

Authors:  Stefano Porzio; Paola Bossù; Paolo Ruggiero; Diana Boraschi; Aldo Tagliabue
Journal:  BMC Biotechnol       Date:  2004-10-30       Impact factor: 2.563

8.  A single point mutation within the coding sequence of cholera toxin B subunit will increase its expression yield.

Authors:  Bita Bakhshi; Mina Boustanshenas; Masoud Ghorbani
Journal:  Iran Biomed J       Date:  2014-07

9.  Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.

Authors:  Julie Liao; Jacob A Gibson; Bradley S Pickering; Paula I Watnick
Journal:  mSphere       Date:  2018-06-06       Impact factor: 4.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.